GlioCART GmbH
CAR-T cell therapy targeting glioblastoma.
Glioblastoma (GBM) is an aggressive and fatal brain cancer, with a median survival of just 12-18 months despite treatment. We have developed a CAR-T cell therapy for GBM targeting the tumors directly while secreting a CD47-blocker to reprogram macrophages. With our therapy, we expect increased survival rates and significantly reduced side effects compared to standard-of-care treatments and other new product developments (e.g. ADCs).Targeting IMPD submission and FIH clinical start within 2025.The company will be a spin-off from University of Basel. Founders: Prof. Dr. Gregor Hutter CMO Dr. Patrice Zeis COODr. Valerio Sabatino CSODieter Willmann CEO
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
No news
No milestones
No Jobs
No videos and documents
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
GlioCART GmbH
CAR-T cell therapy targeting glioblastoma.
Headquarter:
Allschwil
Foundation Date:
November 2025
Technology:
- Biotech
Sectors:
- Biotech
- Cancer
- Drug development platforms
Support received
